BMY - Bristol-Myers Squibb Company Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

BMY

BRISTOL-MYERS SQUIBB COMPANY

NYSE

$64.10

▲ UP 0.72% (0.46)

KEY STATISTICS

Market Cap$130.00 B

52w High$68.64

52w Low$42.52

Dividend Yield4.51%

FrequencyQuarterly

P/E10.81

Volume6.88M

Shares Out.2.04B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christopher S. Boerner

COMPENSATION 2026

Salary$1,586,346

Stock Awards$16,061,399

Incentive Plan Pay$3,754,684

All Other Comp.$477,490

Total$21,879,919

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 1, 1972

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

32,500

PRICE TARGET

Target High$75.00

Target Low$59.00

Target Median$65.00

Target Consensus$68.29

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$12.59B

OCT

THU

SPLIT RECORD

DATE	TYPE	RATIO
2001-08-07	Forward	1000000:951777
1999-03-01	Forward	2:1
1997-03-03	Forward	2:1
1987-06-10	Forward	2:1
1983-05-27	Forward	2:1
1977-05-31	Forward	2:1

PRICE

$64.10 ▲ UP 0.72% (+$0.46)

OVERLAYS

About Bristol-Myers Squibb Company

https://www.bms.com ↗

Bristol-Myers Squibb is a global biopharmaceutical company developing and marketing medicines across hematology, oncology, cardiovascular, immunology, neuroscience, and COVID-19, serving diverse healthcare providers worldwide.

INDUSTRY

Drug Manufacturers - General

A PRODUCT BRISTOL-MYERS SQUIBB COMPANY IS KNOWN FOR

Opdualag (nivolumab and relatlimab-rmbw)

Opdualag, FDA-approved in 2022, is a first-in-class fixed-dose dual immunotherapy combining nivolumab and relatlimab for unresectable or metastatic melanoma, marking a significant advancement in treatment and a key growth product for Bristol-Myers...